Company

About Embolx

Embolx is an emerging commercial-stage medical device company in Silicon Valley developing microcatheters for arterial embolization procedures. Embolx is committed to dramatically improving the treatment of a variety of conditions including cancerous tumors, benign prostatic hyperplasia and uterine fibroids. The Sniper® balloon occlusion microcatheter sets a new standard for precise embolic delivery and superior target filling by controlling pressure to direct blood flow while protecting non-target surrounding tissues. Embolx is a privately held company.

Management Team

Michael Allen
Michael Allen

President & Chief Executive Officer

Michael Allen is a Silicon Valley entrepreneur with 30 years’ experience leading diagnostic and medical device companies from inception to exit. He held the position of President & CEO at Metrika (acquired by Bayer) and XLumena (acquired by Boston Scientific). At ChemTrak, Mr. Allen was the Vice President of R&D which went public in 1993. Prior to that he was a research and development scientist at Syntex. He holds a degree in Biochemistry from University of California Berkeley and has 15 publications, 35 issued and pending patents and six products that are being sold to hospitals, physician offices and over the counter.

Greg Halstead

Greg Halstead

Director of Engineering & Operations

Greg Halstead earned a Master’s degree in Biomedical Engineering and has been working exclusively within the medical device industry. He held positions at VISX, Bacchus Vascular, Topcon Medical and others in capital medical equipment as well as disposables and instrumentation. Mr. Halstead has held director positions in Engineering and Marketing roles leading device projects from inception to commercialization. He has almost 20 years of experience in medical device industry for engineering, regulatory/quality, clinical studies, physician training and marketing.

Michael Lin

Michael Lin

Director of Finance

Michael Lin has over 20 years experience in financial and operational management. Prior to joining Embolx, he was the VP of Finance and Accounting at B-Bridge International. Michael has held various senior positions at Imperito Networks, ArcSoft, Pai Accountancy in addition to co-founding Proficio, a managed security service provider. Mr Lin received his degree from Boston University.

John Layton
John Layton

Director of Marketing

John Layton has over 20 years’ experience in medical device marketing and consumer product development. He has successfully commercialized and launched over 10 medical device products worldwide. Prior to joining Embolx, John served in various leadership roles in EBR Systems, Thoratec, and Boston Scientific. He holds a MBA from Michigan State University.

Ben Felipe
Ben Felipe

Director of Sales

Ben Felipe has over 20 years experience in medical device sales and sales management. He has been instrumental in the commercialization of 7 cardiovascular and endovascular technologies. His experience and leadership spans across keystone companies and the start-up environment: Cordis -J&J, Edwards Lifesciences (EVT), Kensey Nash, Spectranetics, Argon, and CSI. He is a graduate of UC Berkeley.

Board of Directors

Norman Gitis

Chairman

Dr. Norman Gitis serves as the Member of Screening Committee at Band of Angels. He founded and served as President and Chief Executive Officer of Center for Tribology. He is also an Angel Investor. He obtained his Ph.D. (1983) in Mechanical Engineering from the USSR Academy of Sciences in Moscow. He was twice named the CEO of Top20 Fastest Growing Private Companies in Northern California by the Business Journal. Norm is a life member of the engineering society of India and is a visiting professor of two universities in China.

Michael Allen

President & Chief Executive Officer

Michael Allen is a Silicon Valley entrepreneur with 30 years’ experience leading diagnostic and medical device companies from inception to exit. He held the position of President & CEO at Metrika (acquired by Bayer) and XLumena (acquired by Boston Scientific). At ChemTrak, Mr. Allen was the Vice President of R&D which went public in 1993. Prior to that he was a research and development scientist at Syntex. He holds a degree in Biochemistry from University of California Berkeley and has 15 publications, 35 issued and pending patents and six products that are being sold to hospitals, physician offices and over the counter.

Frank Grillo

Secretary

Mr. Grillo is President, CEO and a member of the BOD of AirXpanders. He has over 20 years of experience in the US medical device industry. He previously served for ten years in multiple roles with Boston Scientific Corporation, including Vice President, Marketing for its Women’s Health, Urology/Gynecology Division. Mr. Grillo was then recruited to Kyphon as Vice President, Marketing and Business Development. After Kyphon was acquired by Medtronic, Mr. Grillo then joined Intuitive Surgical Inc where he was VP, Marketing and Business Development for over six years. Most recently, Mr. Grillo was at MRI Interventions, a publicly traded neurological navigation company, where he served as President and CEO. Mr. Grillo holds a Bachelor of Science degree in Chemical Engineering from Tufts University and a Master of Business Administration degree in Marketing, Finance and Operations from the J.L. Kellogg Graduate School of Management at Northwestern University.

Paul Rogan

Board Member

Mr. Rogan was CEO of Equipe Technologies which developed and marketed wafer handling robots. With a total paid in capital of $50K, he sold the company for $250MM. He led Equipe to 75% market share in a field of 20 competitors and achieved a 25% profit margin. He is now a co-founder of E Systems and iRobot. His companies are remarkably cash efficient, allowing them to reach profitability with minimal cash requirements.

Tianhong Xu

Board Member

Dr. Tianhong Xu is a Co‐Founding Partner at VI Ventures. Dr. Xu’s life science experience spanned over 15 years as venture capitalist, UN officer, entrepreneur,research and clinical doctor. He focuses on investments in the medical device, biotech and healthcare service space. He earned his PhD in Molecular and Human Genetics from Baylor College of Medicine in Houston, Texas, and MD from Fudan University.